Testing Ivonescimab with Chemo for Advanced Stomach Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) that has spread or cannot be removed with surgery.
- You have not had any prior chemotherapy for advanced disease (unless you have certain tumor markers, then you may have had one prior treatment).
- You are generally up and active (ECOG performance status 0 or 1).
- Your blood counts, kidney, and liver function are within healthy ranges.
- You are not pregnant, breastfeeding, and will use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) for people with advanced adenocarcinoma of the esophagus, stomach, or gastroesophageal junction. The drug is designed to help the immune system fight cancer. The study is for people who have not had prior treatment for stage IV disease and whose cancer is HER2 negative.
This trial tests whether adding the drug ivonescimab to standard chemotherapy, given before and after surgery, helps shrink tumors and lower the chance of the cancer coming back in people with advanced stomach cancer that can be removed with surgery.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
Hear when a new Metastatic Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.